Seaport Therapeutics, Founded by PureTech, Reports Science Translational Medicine Publication Highlighting GlyphAllo™ (SPT-300) as a First-in-Class Triglyceride-Mimetic Prodrug Achieving Therapeutic Drug Levels in Humans
PureTech Health plc has highlighted a significant scientific milestone achieved by its Founded Entity, Seaport Therapeutics, which recently announced the publication of first-in-human clinical and preclinical data for its investigational candidate GlyphAllo™ (SPT-300) in the prestigious journal Science Translational Medicine. This publication represents a major step forward in validating both the GlyphAllo program and the proprietary Glyph™ drug delivery platform, reinforcing their potential to transform treatment approaches in neuropsychiatric disorders.
The GlyphAllo program originated within PureTech, reflecting the company’s unique hub-and-spoke model of innovation. Through this approach, PureTech identifies clinically validated biological mechanisms and seeks to overcome their limitations through targeted technological innovation. In this case, the Glyph platform was designed to address the well-known pharmacokinetic challenges associated with allopregnanolone, a naturally occurring neurosteroid with demonstrated antidepressant, anxiolytic, and sleep-modulating effects. These foundational innovations have since been advanced by Seaport Therapeutics, which is now leading the clinical development of the program.
The peer-reviewed publication provides a comprehensive overview of GlyphAllo’s development, from early discovery through clinical proof-of-concept. Notably, GlyphAllo is described as the first triglyceride-mimetic prodrug capable of achieving therapeutically relevant drug levels in humans through oral administration. This is a critical advancement, as many promising compounds—including allopregnanolone—have historically been limited by poor oral bioavailability due to extensive first-pass liver metabolism.
According to Steven Paul, M.D., Co-Founder and Board Chair at Seaport Therapeutics, allopregnanolone has already demonstrated clinically meaningful effects in conditions such as postpartum depression, where it has shown rapid onset and significant therapeutic benefits. However, its clinical utility has been constrained by delivery challenges. GlyphAllo has been specifically engineered to overcome these limitations, enabling oral dosing while maintaining the molecule’s beneficial pharmacological properties. This advancement opens the door to exploring allopregnanolone-based therapies in broader indications, including major depressive disorder (MDD).
The scientific work detailed in the publication describes how researchers designed and optimized a series of triglyceride-mimetic prodrug candidates. These compounds were created by conjugating allopregnanolone with lipophilic moieties, allowing them to utilize lymphatic transport pathways rather than traditional hepatic metabolism. Preclinical studies demonstrated that several of these candidates achieved robust lymphatic absorption and plasma release, resulting in therapeutically relevant systemic exposure following oral dosing. These findings validated the core concept behind the Glyph platform—namely, that it can enable oral delivery of compounds previously limited by unfavorable pharmacokinetics.
Further validation came from clinical studies. In Phase 1 trials, GlyphAllo was administered to healthy volunteers across a range of doses, from 70 mg to 1000 mg. The results showed that the drug was generally well tolerated and achieved dose-dependent increases in plasma allopregnanolone levels within a therapeutically relevant range. These findings confirmed that the preclinical advantages of the Glyph platform translated effectively into human subjects.
In addition to safety and pharmacokinetics, the clinical program also explored pharmacodynamic effects. In a Phase 2a proof-of-concept study using the Trier Social Stress Test (TSST), a well-established model for evaluating stress and anxiety responses, a single 375 mg dose of GlyphAllo produced a statistically significant reduction in salivary cortisol levels compared to placebo (p=0.0001). This result demonstrated that the compound can meaningfully modulate physiological stress responses, providing early evidence of its potential therapeutic benefit in neuropsychiatric conditions.
Michael Chen, Ph.D., Co-Founder and Chief Scientific Officer at Seaport Therapeutics, emphasized that these findings not only support the continued development of GlyphAllo but also validate the broader applicability of the Glyph platform. By enabling oral delivery and improving pharmacokinetic profiles, the platform has the potential to transform a wide range of small molecules into clinically viable therapies. This versatility could extend beyond neuropsychiatry into areas such as oncology, immunology, inflammation, metabolic diseases, and obesity.
Building on these encouraging results, Seaport has already initiated a global Phase 2b clinical trial known as BUOY-1. This randomized, double-blind, placebo-controlled study is evaluating the efficacy, safety, and tolerability of GlyphAllo in adults with major depressive disorder, including patients with or without anxious distress. The trial represents a critical next step in determining whether the promising early findings can translate into meaningful clinical outcomes in a larger patient population.
The publication also underscores the collaborative nature of the research effort. In addition to contributions from Seaport scientists, including lead author Jamie Simpson, Ph.D., and co-inventor Daniel Bonner, Ph.D., the work involved collaboration with Monash University under the direction of Christopher Porter, Ph.D., a key figure in the development of the Glyph technology. This partnership highlights the importance of academic-industry collaboration in advancing innovative therapeutic platforms.
Overall, the publication of GlyphAllo data in Science Translational Medicine represents a pivotal moment for both PureTech Health and Seaport Therapeutics. It validates years of research and development efforts and provides a strong scientific foundation for дальней clinical advancement. More broadly, it demonstrates how targeted innovation can unlock the potential of well-understood biological mechanisms, transforming them into practical and scalable therapeutic solutions.
As the development of GlyphAllo progresses, it holds promise as a differentiated treatment option for major depressive disorder, a condition that continues to impose a significant global burden. At the same time, the success of the Glyph platform could pave the way for a new generation of orally available therapies across multiple disease areas, reinforcing PureTech’s mission to translate scientific breakthroughs into meaningful clinical and commercial value.
About the Glyph™ Platform
Glyph is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism otherwise leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity.
For each program, Seaport leverages its Glyph platform to create unique sets of prodrugs with differentiated profiles, including lymphatic transport and conversion characteristics, as potential candidates to advance into preclinical and clinical proof-of-concept studies. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group.
Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release, Molecular Pharmaceutics, and Science Translational Medicine supporting the Glyph platform’s capabilities. See Glyph in action here.
Source Link:https://www.businesswire.com/
